DK0600970T3 - Anvendelse af interleukin-10-analoger eller -antagonister til behandling af endotoksin- eller superantigeninduceret tokscit - Google Patents

Anvendelse af interleukin-10-analoger eller -antagonister til behandling af endotoksin- eller superantigeninduceret tokscit

Info

Publication number
DK0600970T3
DK0600970T3 DK92917650T DK92917650T DK0600970T3 DK 0600970 T3 DK0600970 T3 DK 0600970T3 DK 92917650 T DK92917650 T DK 92917650T DK 92917650 T DK92917650 T DK 92917650T DK 0600970 T3 DK0600970 T3 DK 0600970T3
Authority
DK
Denmark
Prior art keywords
interleukin
superantigen
antagonists
analogs
induced toxicity
Prior art date
Application number
DK92917650T
Other languages
English (en)
Inventor
Hergen Spits
Waal Malefyt Rene De
Maureen Howard
Di-Hwei Hsu
Hiroshi Ishida
Anne O'garra
Albert Zlotnik
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of DK0600970T3 publication Critical patent/DK0600970T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06Antianaemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/54Interleukins [IL]
    • C07K14/5428IL-10
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/16011Herpesviridae
    • C12N2710/16211Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
    • C12N2710/16222New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
DK92917650T 1991-08-06 1992-08-06 Anvendelse af interleukin-10-analoger eller -antagonister til behandling af endotoksin- eller superantigeninduceret tokscit DK0600970T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74212991A 1991-08-06 1991-08-06
PCT/US1992/006378 WO1993002693A2 (en) 1991-08-06 1992-08-06 Use of interleukin-10 analogs or antagonists to treat endotoxin- or superantigen induced toxicity

Publications (1)

Publication Number Publication Date
DK0600970T3 true DK0600970T3 (da) 2000-05-29

Family

ID=24983602

Family Applications (1)

Application Number Title Priority Date Filing Date
DK92917650T DK0600970T3 (da) 1991-08-06 1992-08-06 Anvendelse af interleukin-10-analoger eller -antagonister til behandling af endotoksin- eller superantigeninduceret tokscit

Country Status (17)

Country Link
EP (2) EP0600970B1 (da)
JP (3) JPH07502019A (da)
KR (1) KR100271197B1 (da)
AT (1) ATE187336T1 (da)
AU (1) AU678137B2 (da)
CA (1) CA2115060C (da)
CZ (1) CZ281796B6 (da)
DE (1) DE69230403T2 (da)
DK (1) DK0600970T3 (da)
ES (1) ES2138976T3 (da)
FI (1) FI940519A0 (da)
GR (1) GR3032167T3 (da)
HU (1) HU224437B1 (da)
NO (1) NO315409B1 (da)
PT (1) PT600970E (da)
SK (1) SK282947B6 (da)
WO (1) WO1993002693A2 (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018783A1 (en) * 1992-03-20 1993-09-30 Schering Corporation Use of interleukin-10 to induce the production of interleukin-1 receptor antagonist
WO1994006473A1 (en) * 1992-09-18 1994-03-31 Schering Corporation Restoration of immunocompetency to t helper cells in hiv infected patients
WO1994017773A2 (en) * 1993-02-01 1994-08-18 Université Libre de Bruxelles Use of a pharmaceutical composition comprising an effective amount of interleukin-10, an analog and/or an agonist of interleukin-10
JPH08507930A (ja) * 1993-07-26 1996-08-27 シェリング・コーポレーション ヒトインターロイキン−10のアゴニストおよびアンタゴニスト
AU686816B2 (en) 1994-07-05 1998-02-12 Steeno Research Group A/S Immunomodulators
US5753218A (en) * 1996-05-03 1998-05-19 Schering Corporation Method for treating inflammation
JPWO2002066069A1 (ja) * 2001-02-20 2004-09-24 関西ティー・エル・オー株式会社 炎症・腫瘍性疾患治療剤
AR046833A1 (es) * 2003-11-10 2005-12-28 Schering Corp Anticuerpos anti-interleuquina-10
JP2013511994A (ja) 2009-11-30 2013-04-11 バイオテスト・アクチエンゲゼルシヤフト 全身性エリテマトーデス(sle)を治療するためのヒト化抗il−10抗体
BR112015018834A2 (pt) 2013-03-20 2017-07-18 Hoffmann La Roche método para a detecção de um anticorpo do rato, utilização de uma mistura de anticorpos monoclonais e utilização de um anticorpo

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL94878A (en) * 1989-06-28 2003-01-12 Schering Corp Cytokine synthesis inhibitory factor, antagonists thereof and methods of using same
ZA9010188B (en) * 1989-12-20 1991-08-28 Schering Corp Bcrf1 proteins as inhibitors of interferon-gamma

Also Published As

Publication number Publication date
DE69230403D1 (de) 2000-01-13
HU224437B1 (hu) 2005-09-28
FI940519A7 (fi) 1994-02-04
JP2008013573A (ja) 2008-01-24
WO1993002693A2 (en) 1993-02-18
SK12994A3 (en) 1994-12-07
NO315409B1 (no) 2003-09-01
KR100271197B1 (ko) 2000-11-01
PT600970E (pt) 2000-05-31
JP2004250454A (ja) 2004-09-09
GR3032167T3 (en) 2000-04-27
NO940370L (no) 1994-02-04
CZ281796B6 (cs) 1997-02-12
EP0541214A3 (en) 1993-09-08
AU678137B2 (en) 1997-05-22
AU2441192A (en) 1993-03-02
CA2115060A1 (en) 1993-02-18
HUT66865A (en) 1995-01-30
WO1993002693A3 (en) 1993-07-22
EP0600970A1 (en) 1994-06-15
CZ24394A3 (en) 1995-01-18
SK282947B6 (sk) 2003-01-09
EP0541214A2 (en) 1993-05-12
ES2138976T3 (es) 2000-02-01
ATE187336T1 (de) 1999-12-15
NO940370D0 (no) 1994-02-04
CA2115060C (en) 2003-05-06
EP0600970B1 (en) 1999-12-08
FI940519L (fi) 1994-02-04
DE69230403T2 (de) 2000-05-11
HU9400314D0 (en) 1994-05-30
FI940519A0 (fi) 1994-02-04
JPH07502019A (ja) 1995-03-02

Similar Documents

Publication Publication Date Title
ATE153655T1 (de) Benzensulfonamidderivat
DE69304955D1 (de) Behandlung von neurodegenerativen Erkrankungen
DK0600970T3 (da) Anvendelse af interleukin-10-analoger eller -antagonister til behandling af endotoksin- eller superantigeninduceret tokscit
HU912359D0 (en) The use of flupirtine active agents for treating muscle-tension
DK0665013T3 (da) Behandling af hyperproliferative karsygdomme
DE69213998D1 (de) Dehalogenierung von Organohalogen enthaltenden Verbindungen
BG60249B1 (bg) Тиазолово съединение за лечение на язви
GB8929076D0 (en) Treatment of shock by blocking agents of edrf effect or formation
FI933193A0 (fi) Behandling av neoplastisk sjukdom med interleukin-10
EP0238553A4 (en) TREATMENT OF A CATABOLIC DEREGULATION.
DE69102936D1 (de) Bis(alkyl-substituierte-4-hydroxyphenylthio)alkan-Analoga als Inhibitoren der Kataraktentstehung.
MX9401175A (es) Inhibidores de la acetilcolinesterasa sililada.
DK0538469T3 (da) Sulfonanilidderivat og lægemiddel
KR950704653A (ko) 독성 폐기물의 처리(treatment of toxic wastes)
ES2095938T3 (es) Procedimiento y composiciones para el tratamiento de lesiones.
FI933739A0 (fi) Foerfarande och komposition foer kontrollering av mikroorganismtillvaext
FI824407L (fi) Foerfarande foer framstaellning av vid behandling av magsaor anvaendbara pyrimidinderivat
DE3788035D1 (de) Etodolac zur Hemmung von Gelenkversteifung.